Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: OTCMKTS:ACCP
- CUSIP: N/A
- Web: abeonatherapeutics.com/
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Net Margins: -2,820.97%
- Return on Equity: -21.61%
- Return on Assets: -19.46%
Frequently Asked Questions for Abeona Therapeutics (OTCMKTS:ACCP)
What is Abeona Therapeutics' stock symbol?
Abeona Therapeutics trades on the OTCMKTS under the ticker symbol "ACCP."
Who are some of Abeona Therapeutics' key competitors?
Some companies that are related to Abeona Therapeutics include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), EXACT Sciences (EXAS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI) and Nektar Therapeutics (NKTR).
Who are Abeona Therapeutics' key executives?
Abeona Therapeutics' management team includes the folowing people:
- Steven H. Rouhandeh, Executive Chairman of the Board
- Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
- Jeffrey B. Davis, Chief Operating Officer
- David P. Nowotnik Ph.D., Senior Vice President - Research and Development
- Harrison G. Wehner III, Senior Vice President - Plasma
- Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
- Michelle Berg, Vice President - Communications & Operations
- Andre'a Lucca, Vice President - Communications & Operations
- Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
- Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance
How do I buy Abeona Therapeutics stock?
Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abeona Therapeutics' stock price today?
MarketBeat Community Rating for Abeona Therapeutics (OTCMKTS ACCP)MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Abeona Therapeutics stock can currently be purchased for approximately $0.22.
Consensus Ratings for Abeona Therapeutics (OTCMKTS:ACCP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Abeona Therapeutics (OTCMKTS:ACCP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Abeona Therapeutics (OTCMKTS:ACCP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Abeona Therapeutics (OTCMKTS:ACCP)
Current Year EPS Consensus Estimate: $0.70 EPS
Dividend History for Abeona Therapeutics (OTCMKTS:ACCP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Abeona Therapeutics (OTCMKTS:ACCP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Abeona Therapeutics (OTCMKTS:ACCP)
Latest Headlines for Abeona Therapeutics (OTCMKTS:ACCP)
Abeona Therapeutics (ACCP) Chart for Thursday, July, 20, 2017